Eli Lilly and Company $LLY Shares Sold by Focus Partners Advisor Solutions LLC

Focus Partners Advisor Solutions LLC trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 9.9% in the second quarter, Holdings Channel.com reports. The firm owned 13,962 shares of the company’s stock after selling 1,540 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Eli Lilly and Company were worth $10,889,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Curio Wealth LLC raised its holdings in Eli Lilly and Company by 14,166.7% in the second quarter. Curio Wealth LLC now owns 428 shares of the company’s stock valued at $334,000 after buying an additional 425 shares during the period. Hobart Private Capital LLC boosted its position in Eli Lilly and Company by 25.5% in the 2nd quarter. Hobart Private Capital LLC now owns 2,180 shares of the company’s stock valued at $1,699,000 after buying an additional 443 shares during the last quarter. Peterson Wealth Services grew its stake in Eli Lilly and Company by 1.9% during the 2nd quarter. Peterson Wealth Services now owns 4,600 shares of the company’s stock valued at $3,586,000 after purchasing an additional 84 shares in the last quarter. Richards Merrill & Peterson Inc. grew its position in shares of Eli Lilly and Company by 25.5% during the second quarter. Richards Merrill & Peterson Inc. now owns 767 shares of the company’s stock worth $598,000 after buying an additional 156 shares in the last quarter. Finally, NORTHSTAR ASSET MANAGEMENT Co increased its position in shares of Eli Lilly and Company by 1.7% in the 2nd quarter. NORTHSTAR ASSET MANAGEMENT Co now owns 910 shares of the company’s stock worth $709,000 after purchasing an additional 15 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on LLY. HSBC upped their price target on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. BMO Capital Markets increased their target price on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the company an “outperform” rating in a research note on Monday, October 20th. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Friday. Finally, Morgan Stanley reduced their price objective on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research note on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $938.61.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky acquired 1,000 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares of the company’s stock, valued at $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock valued at $2,894,841 in the last 90 days. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 0.6%

Shares of LLY stock opened at $825.86 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a fifty day moving average of $768.01 and a 200-day moving average of $768.14. The stock has a market cap of $781.65 billion, a price-to-earnings ratio of 53.98, a P/E/G ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.